356 related articles for article (PubMed ID: 11255078)
1. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG
Crit Rev Oncol Hematol; 2001 Apr; 38(1):17-23. PubMed ID: 11255078
[TBL] [Abstract][Full Text] [Related]
2. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A
Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment.
Lynch DH; Yang XD
Semin Oncol; 2002 Feb; 29(1 Suppl 4):47-50. PubMed ID: 11894013
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
Foon KA; Yang XD; Weiner LM; Belldegrun AS; Figlin RA; Crawford J; Rowinsky EK; Dutcher JP; Vogelzang NJ; Gollub J; Thompson JA; Schwartz G; Bukowski RM; Roskos LK; Schwab GM
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):984-90. PubMed ID: 14967460
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
7. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.
Rowinsky EK; Schwartz GH; Gollob JA; Thompson JA; Vogelzang NJ; Figlin R; Bukowski R; Haas N; Lockbaum P; Li YP; Arends R; Foon KA; Schwab G; Dutcher J
J Clin Oncol; 2004 Aug; 22(15):3003-15. PubMed ID: 15210739
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
11. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
12. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
Saadeh CE; Lee HS
Ann Pharmacother; 2007 Apr; 41(4):606-13. PubMed ID: 17355997
[TBL] [Abstract][Full Text] [Related]
13. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.
Ciardiello F; Damiano V; Bianco R; Bianco C; Fontanini G; De Laurentiis M; De Placido S; Mendelsohn J; Bianco AR; Tortora G
J Natl Cancer Inst; 1996 Dec; 88(23):1770-6. PubMed ID: 8944008
[TBL] [Abstract][Full Text] [Related]
16. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
[TBL] [Abstract][Full Text] [Related]
17. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW
J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
Masui H; Kawamoto T; Sato JD; Wolf B; Sato G; Mendelsohn J
Cancer Res; 1984 Mar; 44(3):1002-7. PubMed ID: 6318979
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
20. Panitumumab.
Chua YJ; Cunningham D
Drugs Today (Barc); 2006 Nov; 42(11):711-9. PubMed ID: 17171190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
